Acer Therapeutics Inc. (ACER) [Rocket]

Date Filed	Type	Description
03/29/2021	GN	Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
03/25/2021	GN	Notice of Settlement of Derivative Suits
03/22/2021	GN	Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
03/01/2021	GN	Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
02/11/2021	GN	Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
01/25/2021	GN	Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
12/22/2020	GN	Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
12/17/2020	GN	Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden
10/01/2020	GN	Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital
08/25/2020	GN	Acer Therapeutics to Virtually Present at Upcoming Investor Conferences
07/23/2020	GN	Acer Therapeutics Investors Who Have Held Their Stock Continuously Since at Least September 25, 2017 Are Encouraged to Contact Kehoe Law Firm, P.C.
05/11/2020	GN	Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
03/18/2020	GN	Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA's Office of New Drugs
03/18/2020	GN	Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update